FDA Releases Rules for Biosimilar Product Promotion Guidance
Published Date: 12/10/2025
Notice
Summary
The FDA just released clear rules for companies on how to advertise and label prescription biological drugs, including biosimilars and interchangeable biosimilars. This helps drug makers know what’s allowed when promoting these products, making sure info is honest and easy to understand. The new guidance is official as of December 10, 2025, so affected companies should update their ads soon to avoid any hiccups.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 1 costs, 1 mixed.
New FDA Ad Rules for Biologics
On December 10, 2025, FDA issued final guidance on promotional labeling and advertising for prescription reference biological products, biosimilar products, and interchangeable biosimilar products. The guidance tells firms how to identify products, present study information, present data not in FDA-approved labeling (when consistent with labeling), compare biosimilars and reference products, and submit promotional communications to FDA; the recommendations apply regardless of medium (paper or digital).
Pharmacy Substitution Clarified
The guidance reiterates that an interchangeable biosimilar product may be substituted for the reference product without the prescribing healthcare provider's intervention (section 351(i)(3) of the Public Health Service Act). Decisions about pharmacy-level substitution remain subject to State pharmacy law.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10321 — Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Safety and Effectiveness of MFLUSIVA (Influenza Vaccine, mRNA) Manufactured by Moderna TX Inc.
The FDA is holding a public meeting on June 18, 2026, to talk about the safety and effectiveness of MFLUSIVA, a new flu vaccine made by Moderna. Anyone can watch online and share their thoughts before June 17. This is a big deal for people who get flu shots and could affect how this vaccine is used and approved.
2026-10295 — M11 Clinical Electronic Structured Harmonised Protocol (CeSHarP); International Council for Harmonisation; Guidance for Industry; Availability
The FDA just released a new, easy-to-use digital guide called M11 CeSHarP to help everyone involved in clinical trials share and review study plans faster and clearer. This affects drug companies, researchers, and regulators worldwide by setting a global standard for how trial info is written and shared electronically. The new rules kick in now, aiming to save time and reduce confusion, with no direct cost but big efficiency gains.
2026-10277 — Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
The FDA just released new draft guides to help drug makers design studies proving their generic drugs work like the originals. If you’re in the drug business, now’s your chance to share feedback by July 21, 2026, before these guides become final. These updates aim to speed up drug approvals, potentially saving time and money for companies and patients alike!
2026-10284 — Protein Efficiency Ratio Rat Bioassay Studies To Demonstrate That a New Infant Formula Supports the Quality Factor of Sufficient Biological Quality of Protein; Guidance for Industry; Availability
The FDA just released new guidance to help baby formula makers prove their products have good-quality protein using special rat studies. This update affects formula manufacturers and labs, making it easier and clearer to show their formulas meet nutrition standards. The guidance is effective now, helping companies avoid costly mistakes and speed up getting new formulas to market.
2026-10268 — Notice of Decision Not To Designate Hepatitis Delta Virus Diseases as an Addition to the Current List of Tropical Diseases in the Federal Food, Drug, and Cosmetic Act
The FDA decided not to add Hepatitis Delta Virus (HDV) to the list of tropical diseases because it doesn’t fully meet the rules about market size and who it affects. This means drug makers won’t get special priority review vouchers for HDV treatments right now. People working on HDV drugs should keep an eye out for future updates but won’t see changes or new incentives immediately.
2026-10190 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Patent Term Restoration; Due Diligence Petitions; Filing, Format, and Content of Petitions
The FDA is updating how companies ask for extra patent time when their new drugs or devices take a while to get approved. This affects drug and medical device makers who want to protect their inventions longer. Comments on these changes are open until June 22, 2026, and the update aims to keep the process clear without adding extra costs or delays.
Previous / Next Documents
Previous: 2025-22426 — Agency Information Collection Activities: Proposed Collection; Comment Request
The Centers for Medicare & Medicaid Services (CMS) wants your thoughts on their plan to collect some info from the public. They’re asking for comments by February 9, 2026, to make sure the process is clear, useful, and not too much work. This helps CMS do its job better without wasting anyone’s time or money.
Next: 2025-22428 — Determination Pursuant to Section 102 of the Illegal Immigration Reform and Immigrant Responsibility Act of 1996, as Amended
Starting December 10, 2025, the Department of Homeland Security is speeding up the building of barriers and roads along the Texas border by temporarily skipping some usual rules and laws. This move helps stop illegal crossings and keeps the country safer, focusing on quick action without delays. It affects border communities and aims to boost security without mentioning extra costs or funding changes.